{"gene":"NCR1","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":1999,"finding":"Surface density of NKp46 on NK clones directly correlates with natural cytotoxicity against HLA-class I-unprotected target cells; antibody-mediated masking of NKp46 inhibits cytolysis, establishing NKp46 as a principal activating receptor mediating natural cytotoxicity.","method":"Monoclonal antibody masking assay, NK clone cytotoxicity assay (chromium release)","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional blocking with mAb plus correlation across multiple NK clones and fresh NK cells, replicated across donors and target cell types","pmids":["10359120"],"is_preprint":false},{"year":2001,"finding":"NKp46 ligation on NK cells activates phosphatidylinositol 3-kinase (PI3K), and PI3K inhibitors (LY294002, wortmannin) block NK cell-mediated lysis of autologous antigen-presenting cells and reduce Akt/PKB activation triggered by NKp30 or NKp46 engagement.","method":"Redirected killing assay, PI3K inhibitor treatment, Akt/PKB activation assay","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional assay with pharmacological inhibitors and signaling readout, single lab but two orthogonal methods","pmids":["11385609"],"is_preprint":false},{"year":2002,"finding":"NKp46 receptor expression (mRNA) is upregulated on NK cells in response to M. tuberculosis-infected monocytes, and antibody-mediated masking of NKp46 markedly inhibits NK lysis of infected monocytes, establishing NKp46 as a mediator of NK killing of intracellularly bacterium-infected cells.","method":"RT-PCR for NKp46 mRNA, antibody-blocking cytotoxicity assay","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — blocking antibody functional assay plus mRNA quantification, single lab","pmids":["11907104"],"is_preprint":false},{"year":2003,"finding":"NKp46 directly binds influenza and Sendai virus hemagglutinins in a sialic acid-dependent manner; the interaction is primarily mediated via alpha2,6-linked sialic acid carried on NKp46. Recognition of target cells (both viral and tumor) is confined to the membrane-proximal domain of NKp46. A highly conserved O-glycosylated residue, Thr225, plays a dual critical role in NKp46 interactions with both viral hemagglutinins and unknown tumor ligands through different mechanisms.","method":"Direct binding assay, site-directed mutagenesis of NKp46 residues, sialic acid modification experiments, cytotoxicity assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro binding assays with mutagenesis defining specific residues and glycosylation requirements, multiple viral strains tested","pmids":["14504081"],"is_preprint":false},{"year":2004,"finding":"Rat NKp46 is an activating NK cell receptor; immunoprecipitation demonstrated that rat NKp46 associates with the ITAM-bearing adaptor proteins CD3ζ and FcεRIγ, establishing its signaling mechanism analogous to CD16.","method":"Immunoprecipitation/Western blot, redirected lysis assay, flow cytometry","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal IP demonstrating adaptor association plus functional redirected lysis, single lab","pmids":["15356098"],"is_preprint":false},{"year":2006,"finding":"L-kynurenine, a tryptophan catabolite produced by IDO, prevents cytokine-mediated up-regulation of NKp46 surface expression (at both transcriptional and protein levels) and impairs NK cell killing of targets recognized via NKp46; this effect is specific to NKp46 and NKG2D but not NKp30 or CD16, and is reversible upon washing.","method":"Flow cytometry for receptor expression, NK cytotoxicity assay, RT-PCR for mRNA levels","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor-level and functional readouts at protein and mRNA levels, single lab with multiple orthogonal methods","pmids":["16902152"],"is_preprint":false},{"year":2006,"finding":"NCR1 (mouse ortholog of NKp46) is required for in vivo control of influenza virus infection; Ncr1-deficient mice (both 129/Sv and C57BL/6) succumb to lethal influenza infection, and NK cells accumulate at the infection site as tracked by GFP reporter.","method":"Ncr1(gfp/gfp) knockout mouse, influenza infection survival model, GFP-based NK cell tracking","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic knockout with defined lethal phenotype, replicated in two mouse strains","pmids":["16565719"],"is_preprint":false},{"year":2006,"finding":"Adenosine suppresses NKp46-receptor crosslinking-mediated NK cell cytotoxic activity and cytokine/chemokine production via A2A adenosine receptor signaling, increased cAMP, and activation of PKA isozyme I (PKA I), but not PKA II.","method":"NKp46 receptor crosslinking assay, adenosine receptor pharmacology, PKA subunit blockade","journal":"Immunologic research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor crosslinking functional assay with specific PKA isoform pharmacological dissection, single lab","pmids":["17337770"],"is_preprint":false},{"year":2007,"finding":"NKp46 recognizes influenza hemagglutinin on infected dendritic cells; antibody blockade of NKp46 (along with NKG2D) inhibits CD69 upregulation and IFN-γ production (but not enhanced cytolysis) of resting NK cells activated by influenza-infected DCs.","method":"Antibody-blocking assay, NK cell activation readouts (CD69, IFN-γ, cytolysis), influenza-infected DC co-culture","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional blocking with defined ligand (HA) plus multiple activation readouts, single lab","pmids":["17312110"],"is_preprint":false},{"year":2007,"finding":"NKp46/CD335 is expressed by NK cells across all mouse strains and multiple monkey species; mouse NKp46 triggers NK cell effector function in a redirected lysis assay; NKp46 expression is detected from the immature CD122+NK1.1+DX5- stage onward; human NKp46 promoter drives NK-cell-selective expression in vitro and in vivo in transgenic mice.","method":"Flow cytometry across species, redirected lysis assay, transgenic mice with NKp46 promoter-driven EGFP and diphtheria toxin receptor","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple species characterization, functional triggering assay, in vivo transgenic model with selective NK ablation","pmids":["17360655"],"is_preprint":false},{"year":2008,"finding":"In human decidual NK (dNK) cells, antibody-mediated engagement of NKp46 (but not NKp30) induces intracellular calcium mobilization, perforin polarization, granule exocytosis, and efficient target cell lysis; NKp46-mediated cytotoxicity is co-activated by CD2 but blocked by NKG2A co-engagement. Conversely, NKp30 (but not NKp46) engagement triggers IFN-γ, TNF-α, and chemokine production in dNK cells.","method":"mAb-specific receptor engagement, calcium mobilization assay, perforin polarization, granule exocytosis assay, cytotoxicity assay, cytokine measurement","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal functional readouts with receptor-specific mAb engagement and co-receptor dissection","pmids":["18713971"],"is_preprint":false},{"year":2009,"finding":"NCR1 (mouse NKp46 ortholog) binds to NKp46 ligands expressed on hepatic stellate cells (HSC); NCR1-deficient mice develop enhanced liver fibrosis in a carbon tetrachloride model; murine and human HSC are killed in an NKp46/NCR1-dependent manner as shown by NKp46-Fc fusion protein binding and antibody-blocking cytotoxicity assays.","method":"NCR1/NKp46-Fc fusion protein staining, Ncr1(gfp/gfp) knockout mouse (CCl4 fibrosis model), NK killing assay with antibody blocking","journal":"Gut","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic KO with fibrosis phenotype, in vitro killing assay with receptor blocking, receptor-Fc binding, human and mouse cells","pmids":["22198715"],"is_preprint":false},{"year":2009,"finding":"NKp46 recognizes specific heparan sulfate/heparin sequences on cancer cells; NKp46 binds highly charged HS/heparin structures, with binding affinities approximately one order of magnitude lower than NKp30 and NKp44; HS/heparin binding to NKp46 is relevant for tumor cell binding and NK cell activation.","method":"Microarray with heparan sulfate oligosaccharide library, surface plasmon resonance, NK cell activation assay","journal":"Journal of proteome research","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — SPR quantitative binding assay with defined synthetic HS structures and functional NK activation readout, single lab","pmids":["19196184"],"is_preprint":false},{"year":2009,"finding":"NKp46 is required for in vivo development of type 1 diabetes; NKp46 recognizes an unknown ligand on mouse and human pancreatic β cells, and NKp46 engagement by β cells leads to NK cell degranulation. NCR1-deficient mice show less streptozotocin-induced diabetes, and soluble NKp46 protein injection into NOD mice during early insulitis prevents diabetes development.","method":"Ncr1(gfp/gfp) knockout mouse (streptozotocin diabetes model), NOD mouse model with soluble NKp46 injection, NK degranulation assay","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with defined disease phenotype, soluble receptor competition in vivo, multiple mouse models, human β cell confirmation","pmids":["20023661"],"is_preprint":false},{"year":2009,"finding":"NCR1 is required for in vivo eradication of PD1.6 lymphoma cells; a cell reporter assay identified a NCR1 ligand on PD1.6 lymphoma cells; in Ncr1(gfp/gfp) knockout mice, PD1.6 lymphoma grows progressively whereas wild-type mice reject tumors; PD1.6 cells are less killed in vitro and in vivo in the absence of NKp46/NCR1.","method":"Cell reporter assay for ligand detection, Ncr1(gfp/gfp) knockout mouse tumor model, in vitro and in vivo NK killing assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with in vivo tumor growth phenotype, functional in vitro killing assay, ligand identification by reporter assay","pmids":["19201876"],"is_preprint":false},{"year":2011,"finding":"In human NK cells, NKp46 engagement induces neutrophil apoptosis in a cell-contact-dependent and caspase-dependent manner through the Fas pathway; antibody blockade of NKp46 (along with Fas pathway inhibition) inhibits this NK-induced neutrophil apoptosis.","method":"NK-neutrophil co-culture, antibody blocking of NKp46, caspase activation assay, Fas pathway analysis","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-contact functional assay with receptor-specific blocking and caspase pathway readout, single lab","pmids":["22231698"],"is_preprint":false},{"year":2011,"finding":"Human and murine pancreatic β cells express an unknown NKp46 ligand and are killed in an NKp46-dependent manner; recognition is confined to the membrane-proximal domain and stalk region of NKp46; glycosylated residues Thr125 and Asn216 on NKp46 are critical for β cell ligand recognition.","method":"NKp46-Fc fusion protein binding, site-directed mutagenesis of NKp46 glycosylation sites, NK killing assay with antibody blocking, flow cytometry","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis defining specific glycosylation residues, receptor-Fc binding, functional killing assay, both human and mouse cells","pmids":["21849674"],"is_preprint":false},{"year":2012,"finding":"NKp46 forms microclusters at the immune synapse between NK cells and target cells; overexpression of human NKp46 increases F-actin accumulation at the immune synapse, and knockdown of NKp46 in primary NK cells decreases F-actin recruitment; NKp46 expression linearly correlates with lytic granule polarization to the immune synapse.","method":"Live cell imaging, F-actin staining at immune synapse, NKp46 overexpression and knockdown, lytic granule polarization assay","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — live imaging with gain/loss-of-function and multiple functional readouts, single lab","pmids":["26441997"],"is_preprint":false},{"year":2012,"finding":"A loss-of-function mutation in the Ncr1 gene (identified by N-ethyl-N-nitrosourea mutagenesis and whole-genome sequencing) results in hyperresponsive NK cells with increased antiviral resistance; NKp46 down-regulates NK cell activity by promoting Helios transcription factor expression in NK cells; NKp46 blockade in vivo enhances NK cell reactivity.","method":"ENU mutagenesis screen, whole-genome sequencing, Ncr1 loss-of-function mutant mice, viral infection models, Helios expression analysis, in vivo NKp46 blockade","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — unbiased genetic screen with whole-genome sequencing, in vivo functional validation, transcription factor mechanistic link","pmids":["22267813"],"is_preprint":false},{"year":2012,"finding":"NKp46 and NKp30 on NK cells are required for NK-mediated killing of oHSV-infected glioblastoma cells, as their ligands are upregulated on infected cells; in Ncr1(-/-) mice and an Ncr1(-/-) NK cell adoptive transfer model, HSV titers and oHSV efficacy are increased, demonstrating that NCR1-mediated NK cell activation limits oncolytic virotherapy.","method":"Ncr1(-/-) mouse, antibody blocking of NKp46/NKp30, NK cytotoxicity assay, adoptive transfer model, HSV titer measurement","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO and adoptive transfer with defined functional phenotype, antibody blocking, in vivo and in vitro confirmation","pmids":["23178246"],"is_preprint":false},{"year":2012,"finding":"NKp46/NCR1 is directly involved in killing of B16 melanoma and Lewis lung carcinoma (D122) cells; an unknown ligand for NKp46/NCR1 is expressed on these tumor cells including those generated in vivo; NCR1-deficient mice show impaired control of B16 and D122 metastasis in spontaneous metastasis models.","method":"Ncr1(gfp/gfp) knockout mouse, NKp46-Fc fusion protein staining, spontaneous metastasis models, NK killing assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with in vivo metastasis phenotype, receptor-Fc binding to characterize ligand properties, in vitro and in vivo killing assays","pmids":["22308311"],"is_preprint":false},{"year":2012,"finding":"RUNX3 transcription factor directly regulates NCR1/NKp46 expression; two cis-regulatory elements near the NCR1 gene act as essential promoter and tissue-dependent enhancer/repressor; the enhancer/repressor contains a RUNX recognition motif that preferentially binds RUNX3; dominant-negative RUNX interference decreases Ncr1 expression, and RUNX3 overexpression increases it.","method":"Reporter assay, dominant-negative RUNX expression, RUNX3 overexpression, EMSA/binding to RUNX motif, mRNA quantification","journal":"Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcriptional regulatory mechanism with dominant negative and overexpression, single lab with multiple methods","pmids":["22253448"],"is_preprint":false},{"year":2013,"finding":"Influenza neuraminidase (NA) removes sialic acid residues from NKp46, thereby reducing NKp46 recognition of viral hemagglutinin (HA) and enabling influenza immune evasion; NA inhibitors (used clinically) restore NKp46 recognition by blocking this sialic acid removal; this mechanism was validated in vitro and in vivo.","method":"NA inhibitor experiments (in vitro and in vivo), sialic acid analysis, NKp46-HA recognition assay, influenza infection model","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 / Strong — mechanistic characterization of sialic acid removal from NKp46 by NA with pharmacological rescue, in vitro and in vivo validation","pmids":["23602571"],"is_preprint":false},{"year":2013,"finding":"Ncr1 recognizes influenza virus in a sialic acid-dependent manner; N-glycosylation is important for Ncr1 binding to viral hemagglutinin, but none of the predicted N-glycosylated residues are individually essential, indicating other unidentified N-glycosylated residues mediate recognition; N-glycosylation plays little role in Ncr1 recognition of mouse tumor cell lines.","method":"Mutagenesis of predicted N-glycosylation sites, sialic acid-dependent binding assay, influenza infection of Ncr1 knockout mice","journal":"PLoS one","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — mutagenesis with binding assay, but key residues not fully identified, single lab","pmids":["22615821"],"is_preprint":false},{"year":2014,"finding":"Type I IFN signaling directly on T cells protects them from NCR1-mediated NK cell killing; Ifnar1(-/-) T cells exhibit elevated NCR1 ligand expression upon LCMV infection, rendering them targets for NCR1-dependent NK cell attack; NK cell depletion fully restores early expansion of Ifnar1(-/-) T cells, and NCR1 mediates the perforin-dependent killing.","method":"Ifnar1(-/-) mice, NK cell depletion, NCR1-blocking experiments, LCMV infection model, NCR1 ligand expression assay","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with NK depletion epistasis, NCR1 ligand upregulation mechanistic link, in vivo LCMV infection model","pmids":["24909889"],"is_preprint":false},{"year":2014,"finding":"NKp46-deficient mice show exacerbated graft-versus-host disease (GVHD) with rapid mortality from commensal bacterial infection after HSCT; the exacerbated GVHD results from altered immune cell responses to stimulation by immature dendritic cells in the absence of NKp46.","method":"Ncr1(gfp/gfp) knockout mouse, HSCT model, GVHD assessment, bacterial infection analysis, DC stimulation assay","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with in vivo GVHD phenotype and partial mechanistic link to DC stimulation, single lab","pmids":["24882008"],"is_preprint":false},{"year":2016,"finding":"NKp46 and its mouse ortholog NCR1 directly recognize C. glabrata adhesins Epa1, Epa6, and Epa7 as fungal ligands; NCR1-knockout mice show impaired control of C. glabrata infection in vitro and in vivo, and clearance of systemic infections depends on Epa1/6/7 recognition by NCR1.","method":"NCR1 knockout mouse (in vitro/in vivo C. glabrata infection), receptor-ligand binding with defined fungal adhesins, fungal infection survival assay","journal":"Cell host & microbe","confidence":"High","confidence_rationale":"Tier 2 / Strong — specific ligand identification with genetic KO validation in vitro and in vivo, defined molecular interaction","pmids":["27736647"],"is_preprint":false},{"year":2016,"finding":"Neutrophil-derived cathepsin G (but not elastase or proteinase 3) cleaves NKp46 on NK cells in a time- and concentration-dependent manner, severely impairing NKp46-mediated IFN-γ production and NK cell degranulation; cystic fibrosis patient sputa (high in cathepsin G) also downregulate NKp46 on NK cells.","method":"Flow cytometry, Western blot, mass spectrometry, NK cell functional assay, CF patient sputum treatment","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — protease-specific cleavage identified by mass spectrometry with functional consequence, single lab","pmids":["27587403"],"is_preprint":false},{"year":2017,"finding":"NKp46 binds complement factor P (CFP/properdin), a soluble plasma glycoprotein; NKp46+ group 1 ILCs are required for survival of Neisseria meningitidis infection in mice, and the beneficial effects of CFP treatment in Nm infection are dependent on NKp46 and NKp46+ ILCs.","method":"Binding assay (NKp46-CFP interaction), NKp46/NCR1-deficient mice, Nm infection survival model, CFP treatment experiments","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct binding of soluble ligand identified with genetic KO validation in vivo infection model, CFP-rescue experiment","pmids":["28480349"],"is_preprint":false},{"year":2018,"finding":"NKp46 signaling (via human NKp46 and mouse Ncr1) induces IFN-γ secretion from intratumoral NK cells; NKp46/Ncr1-mediated IFN-γ production leads to increased expression of fibronectin 1 (FN1) in tumors, altering primary tumor architecture and decreasing metastasis formation; IFN-γ injection or transgenic Ncr1 overexpression in mice reduces metastasis.","method":"Reflectance confocal microscopy (in vivo imaging), Ncr1 knockout mouse, IFN-γ injection, Ncr1 transgenic overexpression, FN1 expression analysis","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo imaging with genetic KO and transgenic overexpression, IFN-γ injection rescue, defined FN1 molecular mechanism","pmids":["29329948"],"is_preprint":false},{"year":2018,"finding":"NKG2D specifically sets the activation threshold for NCR1 (NKp46) through a process requiring the adaptor DAP12; NKG2D engagement before the immature NK cell stage increases CD3ζ expression, and reduced CD3ζ in Klrk1(-/-) (NKG2D-deficient) mice is associated with enhanced NCR1 signal transduction; CD3ζ deficiency results in hyper-responsiveness to NCR1 stimulation.","method":"Klrk1(-/-) mouse, DAP12-deficient mouse, CD3ζ expression analysis, in vitro NCR1 stimulation, MCMV and tumor challenge models","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with multiple KO strains, CD3ζ adaptor mechanistic link, replicated across tumor and viral infection models","pmids":["30224819"],"is_preprint":false},{"year":2018,"finding":"NKp46 controls TRAIL expression on ILC1s; in NKp46-deficient mice, ILC1s fail to express normal TRAIL surface levels, resulting in diminished cytotoxicity toward TRAIL receptor-positive targets.","method":"NKp46-deficient mouse, TRAIL expression analysis on ILC1s, cytotoxicity assay against TRAIL receptor-positive targets","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with specific molecular (TRAIL) and functional (cytotoxicity) readouts, single lab","pmids":["29661825"],"is_preprint":false},{"year":2011,"finding":"Poxviral hemagglutinin (HA) from vaccinia virus and ectromelia virus acts as a ligand for NKp46 (and NKp30); poxviral HA on infected cell surfaces or as soluble protein stimulates NKp46-triggered activation while blocking NKp30 activation, demonstrating differential receptor-ligand effects; this was validated using NK cells with selectively silenced NCR expression and NCR-CD3ζ reporter cells.","method":"NCR-CD3ζ reporter cell assay, NCR-specific siRNA silencing, recombinant soluble HA, NK cell activation assay","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter cell assay plus silenced NCR expression, defined recombinant ligand, single lab","pmids":["21901096"],"is_preprint":false},{"year":2023,"finding":"NKp46 recognizes externalized calreticulin (ecto-CRT) on the cell surface as its endogenous ligand; ecto-CRT translocates from the ER to the cell membrane during ER stress (hallmark of chemotherapy-induced immunogenic cell death, flavivirus infection, and senescence); NKp46 specifically binds the P domain of ecto-CRT and caps with ecto-CRT at NK immune synapses; NCR1-deficient human and mouse NK cells are impaired in killing of ZIKV-infected, ER-stressed, senescent, and ecto-CRT-expressing cancer cells; NKp46 recognition of ecto-CRT controls B16 melanoma and RAS-driven lung cancers in vivo.","method":"Co-immunoprecipitation, NKp46-ecto-CRT binding assay, CALR knockout/knockdown, GPI-anchored CRT ectopic expression, NK immune synapse imaging, NCR1-deficient mouse tumor models, ZIKV infection model","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — endogenous ligand identified by multiple orthogonal methods (binding, KO, KD, ectopic expression, mutagenesis of P domain, immune synapse imaging) in single rigorous study, in vivo validation in multiple models","pmids":["37020026"],"is_preprint":false},{"year":2018,"finding":"MiR-224 overexpression in NK cells reduces NCR1/NKp46 expression; HIF-1α increases miR-224 levels to suppress NCR1, thereby inhibiting NK cell killing of prostate cancer; dual luciferase reporter assay confirmed miR-224 directly targets the NCR1 3'UTR.","method":"miRNA overexpression, dual luciferase reporter assay, flow cytometry, NK cytotoxicity assay","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — luciferase reporter and overexpression, single lab, limited mechanistic follow-up","pmids":["29885835"],"is_preprint":false},{"year":2018,"finding":"MiR-544 directly targets RUNX3 and negatively regulates NCR1/NKp46 in NK cells; miR-544 overexpression inhibits NK cytotoxicity by downregulating IFN-γ and reducing NCR1, promoting immune escape of liver cancer cells in vivo and in vitro.","method":"miRNA mimic/inhibitor transfection, qRT-PCR, Western blot, flow cytometry, NK cytotoxicity assay, mouse liver cancer model","journal":"Cancer cell international","confidence":"Low","confidence_rationale":"Tier 3 / Weak — indirect regulation through miR-544/RUNX3/NCR1 axis, single lab with limited mechanistic depth on NCR1 itself","pmids":["29636640"],"is_preprint":false},{"year":2010,"finding":"NKp46 ligation on NK cells in Sézary syndrome malignant CD4+ T lymphocytes delivers an inhibitory signal suppressing CD3-induced proliferation; this inhibition correlates with decreased phosphorylation of the CD3ζ chain associated with NKp46 and/or the TCR/CD3 complex.","method":"mAb-specific NKp46 engagement, proliferation assay, CD3ζ phosphorylation analysis","journal":"Journal of investigative dermatology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — NKp46 on malignant T cells (atypical context), single Co-IP/phosphorylation readout, single lab","pmids":["21191411"],"is_preprint":false}],"current_model":"NCR1/NKp46 is a conserved activating NK cell receptor that signals through ITAM-bearing adaptors (CD3ζ and FcεRIγ) and PI3K/Akt to trigger cytotoxicity and cytokine secretion; it recognizes multiple ligands including viral hemagglutinins (via α2,6-linked sialic acid on NKp46 itself), externalized calreticulin (ecto-CRT, the principal endogenous danger ligand), complement factor P (properdin), fungal adhesins (Epa1/6/7 on C. glabrata), heparan sulfate proteoglycans on tumor cells, and unknown ligands on pancreatic β cells, hepatic stellate cells, and tumor cells; its activation threshold and TRAIL expression are calibrated by NKG2D through a DAP12–CD3ζ developmental axis; the receptor forms microclusters at the immune synapse to orchestrate F-actin recruitment and lytic granule polarization; NKp46 sialylation is required for hemagglutinin binding and is exploited by influenza neuraminidase as an immune-evasion mechanism; RUNX3 drives NK-cell-specific transcription of the NCR1 gene; and in vivo, NKp46/NCR1 is essential for control of influenza infection, type 1 diabetes, tumor metastasis, C. glabrata infection, and liver fibrosis, and it restrains GVHD and regulates adaptive T cell responses."},"narrative":{"mechanistic_narrative":"NCR1 (NKp46/CD335) is a principal activating receptor of natural killer cells and group 1 innate lymphoid cells that triggers natural cytotoxicity and cytokine secretion against virally infected, tumorigenic, and stressed cells [PMID:10359120, PMID:17360655]. Receptor engagement associates with the ITAM-bearing adaptors CD3ζ and FcεRIγ and activates PI3K/Akt signaling, driving calcium mobilization, granule polarization, and target lysis [PMID:15356098, PMID:11385609, PMID:18713971]; at the immune synapse NKp46 forms microclusters that recruit F-actin and direct lytic granules toward the target cell [PMID:26441997]. NKp46 recognizes a diverse ligand repertoire: influenza, Sendai, and poxviral hemagglutinins via sialic acid and O-/N-glycosylation on the receptor itself [PMID:14504081, PMID:21901096, PMID:22615821], heparan sulfate structures and unknown ligands on tumor cells [PMID:19196184, PMID:22308311, PMID:19201876], ligands on hepatic stellate cells and pancreatic β cells [PMID:22198715, PMID:21849674, PMID:20023661], fungal Epa adhesins of C. glabrata [PMID:27736647], complement factor P [PMID:28480349], and the endogenous danger ligand externalized calreticulin, which it binds via the CRT P domain on ER-stressed, senescent, infected, and dying cells [PMID:37020026]. Through these recognition events NCR1 is required in vivo for control of influenza infection, type 1 diabetes, liver fibrosis, fungal infection, and tumor metastasis, the latter in part through IFN-γ-driven fibronectin remodeling of tumor architecture [PMID:16565719, PMID:20023661, PMID:22198715, PMID:27736647, PMID:29329948], while also restraining graft-versus-host disease and shaping adaptive T cell responses through perforin-dependent killing of type-I-IFN-unprotected T cells [PMID:24882008, PMID:24909889]. Receptor abundance and signaling are tightly calibrated transcriptionally by RUNX3 [PMID:22253448], developmentally by an NKG2D–DAP12–CD3ζ axis that sets the NCR1 activation threshold and controls ILC1 TRAIL expression [PMID:30224819, PMID:29661825], and post-translationally by influenza neuraminidase desialylation and neutrophil cathepsin G cleavage as immune-evasion mechanisms [PMID:23602571, PMID:27587403].","teleology":[{"year":1999,"claim":"Established NKp46 as the principal activating receptor responsible for natural cytotoxicity against HLA-class-I-deficient targets, defining its core cellular role.","evidence":"mAb masking and chromium-release cytotoxicity across NK clones","pmids":["10359120"],"confidence":"High","gaps":["Did not identify the signaling adaptor or downstream pathway","Endogenous ligand unidentified"]},{"year":2001,"claim":"Connected NKp46 ligation to an intracellular signaling pathway by showing it activates PI3K/Akt required for target lysis.","evidence":"Redirected killing with PI3K inhibitors and Akt activation readout","pmids":["11385609"],"confidence":"Medium","gaps":["Pharmacological inhibitors only","Did not define receptor-proximal adaptor coupling to PI3K"]},{"year":2003,"claim":"Identified the first molecular ligands (viral hemagglutinins) and showed recognition depends on α2,6-sialic acid and glycosylation on the receptor itself, mapping interactions to the membrane-proximal domain and Thr225.","evidence":"Direct binding assays with site-directed mutagenesis and sialic acid modification","pmids":["14504081"],"confidence":"High","gaps":["Tumor ligand remained unknown","Endogenous self-ligand not defined"]},{"year":2004,"claim":"Defined the signaling mechanism by demonstrating association with the ITAM-bearing adaptors CD3ζ and FcεRIγ, analogous to CD16.","evidence":"Reciprocal immunoprecipitation and redirected lysis in rat NKp46","pmids":["15356098"],"confidence":"Medium","gaps":["Rat ortholog; human stoichiometry not quantified","Link from ITAM to PI3K not traced"]},{"year":2006,"claim":"Provided in vivo proof that NCR1 is essential for host defense, with knockout mice dying of influenza infection.","evidence":"Ncr1(gfp/gfp) knockout mice in lethal influenza model across two strains","pmids":["16565719"],"confidence":"High","gaps":["Did not establish which viral ligand mediates protection in vivo","NK effector mechanism not dissected in vivo"]},{"year":2006,"claim":"Showed receptor surface levels are environmentally tunable, as the IDO metabolite L-kynurenine and adenosine/A2A-cAMP-PKA I signaling suppress NKp46 expression and function.","evidence":"Flow cytometry, RT-PCR, crosslinking assays with receptor and PKA-subunit pharmacology","pmids":["16902152","17337770"],"confidence":"Medium","gaps":["Mechanism of transcriptional suppression unresolved","Single-lab pharmacological dissection"]},{"year":2009,"claim":"Extended NCR1's in vivo roles to autoimmunity, tumor surveillance, and tissue fibrosis by linking it to β-cell killing in diabetes, lymphoma rejection, and hepatic stellate cell killing.","evidence":"Ncr1 knockout disease models (streptozotocin/NOD diabetes, PD1.6 lymphoma, CCl4 fibrosis) with NKp46-Fc ligand staining","pmids":["20023661","19201876","22198715"],"confidence":"High","gaps":["Endogenous ligands on β cells, lymphoma, and stellate cells remained molecularly unidentified"]},{"year":2009,"claim":"Characterized heparan sulfate/heparin as a class of tumor-relevant NKp46 ligands and quantified binding.","evidence":"HS oligosaccharide microarray, surface plasmon resonance, and NK activation","pmids":["19196184"],"confidence":"Medium","gaps":["Affinities lower than NKp30/NKp44; physiological relevance on specific tumors not fully defined"]},{"year":2011,"claim":"Refined ligand-recognition determinants by mapping β-cell ligand binding to the membrane-proximal/stalk region and specific glycosylated residues Thr125 and Asn216.","evidence":"NKp46-Fc binding with glycosylation-site mutagenesis and killing assays in human and mouse cells","pmids":["21849674"],"confidence":"High","gaps":["β-cell ligand identity still unknown","Mechanistic basis for glycan dependence unresolved"]},{"year":2012,"claim":"Revealed a self-limiting regulatory function: an Ncr1 loss-of-function mutation produces hyperresponsive NK cells, with NKp46 promoting inhibitory Helios expression.","evidence":"ENU mutagenesis, whole-genome sequencing, viral challenge, and in vivo NKp46 blockade","pmids":["22267813"],"confidence":"High","gaps":["Pathway linking NKp46 to Helios transcription not defined"]},{"year":2012,"claim":"Defined the synaptic and transcriptional basis of NKp46 action by linking it to F-actin recruitment and lytic granule polarization, and to RUNX3-driven NK-specific transcription.","evidence":"Live imaging with NKp46 gain/loss-of-function; reporter assays and EMSA with RUNX3 manipulation","pmids":["26441997","22253448"],"confidence":"Medium","gaps":["Direct molecular link from microclusters to actin machinery not detailed","Single-lab transcriptional data"]},{"year":2012,"claim":"Established NCR1's role in tumor metastasis control and showed it limits oncolytic virotherapy by recognizing ligands on infected/tumor cells.","evidence":"Ncr1 knockout spontaneous-metastasis and oHSV glioblastoma models with NKp46-Fc staining","pmids":["22308311","23178246"],"confidence":"High","gaps":["Tumor and oHSV-induced ligands not molecularly identified"]},{"year":2013,"claim":"Uncovered an influenza immune-evasion mechanism whereby viral neuraminidase desialylates NKp46 to abolish HA recognition, reversible by clinical NA inhibitors.","evidence":"NA inhibitor experiments in vitro and in vivo with sialic acid and recognition assays","pmids":["23602571","22615821"],"confidence":"High","gaps":["Precise N-glycosylated residues mediating HA recognition not fully identified"]},{"year":2014,"claim":"Defined an immunoregulatory role in adaptive immunity: NCR1 mediates perforin-dependent killing of T cells lacking type I IFN protection.","evidence":"Ifnar1(-/-) mice with NK depletion epistasis and NCR1 blockade in LCMV infection","pmids":["24909889"],"confidence":"High","gaps":["NCR1 ligand upregulated on IFN-unprotected T cells not identified"]},{"year":2016,"claim":"Identified the first defined microbial protein ligands (C. glabrata Epa1/6/7 adhesins) and established NCR1 in antifungal defense.","evidence":"NCR1 knockout C. glabrata infection models with defined adhesin binding","pmids":["27736647"],"confidence":"High","gaps":["Receptor binding interface for Epa adhesins not structurally mapped"]},{"year":2016,"claim":"Demonstrated a host protease evasion route in which neutrophil cathepsin G cleaves NKp46 and impairs NK function, relevant to cystic fibrosis.","evidence":"Protease specificity by mass spectrometry, Western blot, and CF sputum functional assays","pmids":["27587403"],"confidence":"Medium","gaps":["Cleavage site and protease-resistant variants not defined","Single lab"]},{"year":2017,"claim":"Identified a soluble plasma ligand, complement factor P (properdin), linking NKp46+ ILCs to antibacterial survival.","evidence":"NKp46-CFP binding assay with knockout mice and CFP-rescue in Neisseria infection","pmids":["28480349"],"confidence":"High","gaps":["Functional consequence of CFP binding for downstream signaling not detailed"]},{"year":2018,"claim":"Established a downstream effector mechanism for metastasis control: NKp46-driven IFN-γ increases tumor fibronectin and remodels tumor architecture.","evidence":"In vivo confocal imaging, Ncr1 knockout/transgenic overexpression, IFN-γ injection rescue","pmids":["29329948"],"confidence":"High","gaps":["Triggering ligand on the relevant tumors not identified"]},{"year":2018,"claim":"Defined developmental calibration of the receptor: NKG2D sets the NCR1 activation threshold via DAP12-dependent CD3ζ levels, and NKp46 controls ILC1 TRAIL expression.","evidence":"Klrk1(-/-) and DAP12-deficient mice with CD3ζ analysis and MCMV/tumor challenge; TRAIL/cytotoxicity in NKp46-deficient ILC1s","pmids":["30224819","29661825"],"confidence":"High","gaps":["Molecular basis of how CD3ζ abundance tunes NCR1 signal strength not fully resolved"]},{"year":2018,"claim":"Implicated microRNA circuits (miR-224 via HIF-1α, miR-544 via RUNX3) in tumor-driven suppression of NCR1 expression.","evidence":"miRNA mimics/inhibitors with luciferase reporters and NK cytotoxicity assays","pmids":["29885835","29636640"],"confidence":"Low","gaps":["Single-lab reporter/overexpression studies with limited mechanistic follow-up","In vivo physiological relevance of these miRNA axes not established"]},{"year":2023,"claim":"Identified the principal endogenous danger ligand: externalized calreticulin, bound via its P domain on ER-stressed, senescent, infected, and dying cells, unifying NCR1's recognition of stressed self.","evidence":"Co-IP, binding assays, CALR KO/KD, GPI-anchored CRT ectopic expression, synapse imaging, and NCR1-deficient tumor/ZIKV models","pmids":["37020026"],"confidence":"High","gaps":["Relationship between ecto-CRT and the many previously reported unidentified cellular ligands not reconciled","Structural detail of the NKp46–CRT P-domain interface not resolved"]},{"year":null,"claim":"The molecular identities of multiple reported endogenous ligands (on tumor cells, hepatic stellate cells, β cells, and IFN-unprotected T cells) and how they relate to ecto-CRT remain unresolved, as does the structural basis for NCR1's glycan-dependent multi-ligand recognition.","evidence":"","pmids":[],"confidence":"High","gaps":["Several disease-relevant ligands remain molecularly uncharacterized","No high-resolution structure of NCR1 with an endogenous ligand","Mechanism integrating diverse ligand inputs into a single ITAM signal undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,9,10]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[3,32,23]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[11,20,33]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,4,17]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,6,13,26]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,4,30]}],"complexes":[],"partners":["CD247","FCER1G","CALR","NKG2D","DAP12","RUNX3","CFP"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O76036","full_name":"Natural cytotoxicity triggering receptor 1","aliases":["Lymphocyte antigen 94 homolog","NK cell-activating receptor","Natural killer cell p46-related protein","NK-p46","NKp46","hNKp46"],"length_aa":304,"mass_kda":34.5,"function":"Cytotoxicity-activating receptor that may contribute to the increased efficiency of activated natural killer (NK) cells to mediate tumor cell lysis","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/O76036/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NCR1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NCR1","total_profiled":1310},"omim":[{"mim_id":"611550","title":"NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NCR3","url":"https://www.omim.org/entry/611550"},{"mim_id":"606234","title":"IKAROS FAMILY ZINC FINGER 2; IKZF2","url":"https://www.omim.org/entry/606234"},{"mim_id":"605397","title":"CD226 ANTIGEN; CD226","url":"https://www.omim.org/entry/605397"},{"mim_id":"604945","title":"KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, TWO DOMAINS, LONG CYTOPLASMIC TAIL, 4; KIR2DL4","url":"https://www.omim.org/entry/604945"},{"mim_id":"604530","title":"NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NCR1","url":"https://www.omim.org/entry/604530"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in single","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":3.3}],"url":"https://www.proteinatlas.org/search/NCR1"},"hgnc":{"alias_symbol":["NK-p46","NKP46","CD335"],"prev_symbol":["LY94"]},"alphafold":{"accession":"O76036","domains":[{"cath_id":"2.60.40.10","chopping":"27-119","consensus_level":"high","plddt":97.1515,"start":27,"end":119},{"cath_id":"2.60.40.10","chopping":"122-212","consensus_level":"high","plddt":96.932,"start":122,"end":212}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O76036","model_url":"https://alphafold.ebi.ac.uk/files/AF-O76036-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O76036-F1-predicted_aligned_error_v6.png","plddt_mean":83.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NCR1","jax_strain_url":"https://www.jax.org/strain/search?query=NCR1"},"sequence":{"accession":"O76036","fasta_url":"https://rest.uniprot.org/uniprotkb/O76036.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O76036/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O76036"}},"corpus_meta":[{"pmid":"19029904","id":"PMC_19029904","title":"Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin.","date":"2008","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19029904","citation_count":479,"is_preprint":false},{"pmid":"16565719","id":"PMC_16565719","title":"Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1.","date":"2006","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16565719","citation_count":435,"is_preprint":false},{"pmid":"17360655","id":"PMC_17360655","title":"Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17360655","citation_count":369,"is_preprint":false},{"pmid":"31155232","id":"PMC_31155232","title":"Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity.","date":"2019","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/31155232","citation_count":367,"is_preprint":false},{"pmid":"10359120","id":"PMC_10359120","title":"NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells.","date":"1999","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10359120","citation_count":341,"is_preprint":false},{"pmid":"16902152","id":"PMC_16902152","title":"The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16902152","citation_count":332,"is_preprint":false},{"pmid":"22021440","id":"PMC_22021440","title":"Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22021440","citation_count":291,"is_preprint":false},{"pmid":"17875681","id":"PMC_17875681","title":"The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17875681","citation_count":275,"is_preprint":false},{"pmid":"20142427","id":"PMC_20142427","title":"IL-7 and IL-15 independently program the differentiation of intestinal CD3-NKp46+ cell subsets from Id2-dependent precursors.","date":"2010","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20142427","citation_count":261,"is_preprint":false},{"pmid":"20638936","id":"PMC_20638936","title":"Imbalance of NKp44(+)NKp46(-) and NKp44(-)NKp46(+) natural killer cells in the intestinal mucosa of patients with Crohn's disease.","date":"2010","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/20638936","citation_count":199,"is_preprint":false},{"pmid":"24909889","id":"PMC_24909889","title":"Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1.","date":"2014","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/24909889","citation_count":198,"is_preprint":false},{"pmid":"26458769","id":"PMC_26458769","title":"Unique and redundant functions of NKp46+ ILC3s in models of intestinal inflammation.","date":"2015","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26458769","citation_count":188,"is_preprint":false},{"pmid":"14504081","id":"PMC_14504081","title":"The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14504081","citation_count":187,"is_preprint":false},{"pmid":"21127177","id":"PMC_21127177","title":"A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21127177","citation_count":178,"is_preprint":false},{"pmid":"19531227","id":"PMC_19531227","title":"Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions.","date":"2009","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19531227","citation_count":171,"is_preprint":false},{"pmid":"23178246","id":"PMC_23178246","title":"NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.","date":"2012","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23178246","citation_count":168,"is_preprint":false},{"pmid":"22267813","id":"PMC_22267813","title":"Tuning of natural killer cell reactivity by NKp46 and Helios calibrates T cell responses.","date":"2012","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/22267813","citation_count":162,"is_preprint":false},{"pmid":"17312110","id":"PMC_17312110","title":"NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17312110","citation_count":154,"is_preprint":false},{"pmid":"20023661","id":"PMC_20023661","title":"The activating receptor NKp46 is essential for the development of type 1 diabetes.","date":"2009","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20023661","citation_count":150,"is_preprint":false},{"pmid":"21685873","id":"PMC_21685873","title":"Identity, regulation and in vivo function of gut NKp46+RORγt+ and NKp46+RORγt- lymphoid cells.","date":"2011","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/21685873","citation_count":147,"is_preprint":false},{"pmid":"37020026","id":"PMC_37020026","title":"The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells.","date":"2023","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/37020026","citation_count":146,"is_preprint":false},{"pmid":"29329948","id":"PMC_29329948","title":"NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis.","date":"2018","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/29329948","citation_count":146,"is_preprint":false},{"pmid":"22308311","id":"PMC_22308311","title":"Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22308311","citation_count":137,"is_preprint":false},{"pmid":"22198715","id":"PMC_22198715","title":"NKp46-mediated killing of human and mouse hepatic stellate cells attenuates liver fibrosis.","date":"2011","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/22198715","citation_count":137,"is_preprint":false},{"pmid":"19196184","id":"PMC_19196184","title":"Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan sulfate/heparin sequences.","date":"2009","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/19196184","citation_count":132,"is_preprint":false},{"pmid":"19201876","id":"PMC_19201876","title":"Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19201876","citation_count":125,"is_preprint":false},{"pmid":"26662852","id":"PMC_26662852","title":"NKp46(+) natural killer cells attenuate metabolism-induced hepatic fibrosis by regulating macrophage activation in mice.","date":"2016","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/26662852","citation_count":123,"is_preprint":false},{"pmid":"11907104","id":"PMC_11907104","title":"The NKp46 receptor contributes to NK cell lysis of mononuclear phagocytes infected with an intracellular bacterium.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11907104","citation_count":119,"is_preprint":false},{"pmid":"31689241","id":"PMC_31689241","title":"NKp46-expressing human gut-resident intraepithelial Vδ1 T cell subpopulation exhibits high antitumor activity against colorectal cancer.","date":"2019","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/31689241","citation_count":116,"is_preprint":false},{"pmid":"24038093","id":"PMC_24038093","title":"TCF-1 controls ILC2 and NKp46+RORγt+ innate lymphocyte differentiation and protection in intestinal inflammation.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24038093","citation_count":115,"is_preprint":false},{"pmid":"18713971","id":"PMC_18713971","title":"Critical and differential roles of NKp46- and NKp30-activating receptors expressed by uterine NK cells in early pregnancy.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18713971","citation_count":111,"is_preprint":false},{"pmid":"11385609","id":"PMC_11385609","title":"NK cell-mediated lysis of autologous antigen-presenting cells is triggered by the engagement of the phosphatidylinositol 3-kinase upon ligation of the natural cytotoxicity receptors NKp30 and NKp46.","date":"2001","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11385609","citation_count":110,"is_preprint":false},{"pmid":"17442558","id":"PMC_17442558","title":"Natural killer cells: from CD3(-)NKp46(+) to post-genomics meta-analyses.","date":"2007","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17442558","citation_count":108,"is_preprint":false},{"pmid":"14991596","id":"PMC_14991596","title":"NKp46 defines a subset of bovine leukocytes with natural killer cell characteristics.","date":"2004","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14991596","citation_count":108,"is_preprint":false},{"pmid":"21168454","id":"PMC_21168454","title":"Reduced frequencies of NKp30+NKp46+, CD161+, and NKG2D+ NK cells in acute HCV infection may predict viral clearance.","date":"2010","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/21168454","citation_count":106,"is_preprint":false},{"pmid":"31201208","id":"PMC_31201208","title":"KLRG1 and NKp46 discriminate subpopulations of human CD117+CRTH2- ILCs biased toward ILC2 or ILC3.","date":"2019","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31201208","citation_count":104,"is_preprint":false},{"pmid":"30255106","id":"PMC_30255106","title":"Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer.","date":"2018","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/30255106","citation_count":104,"is_preprint":false},{"pmid":"17337770","id":"PMC_17337770","title":"Adenosine-mediated inhibition of cytotoxic activity and cytokine production by IL-2/NKp46-activated NK cells: involvement of protein kinase A isozyme I (PKA I).","date":"2006","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/17337770","citation_count":103,"is_preprint":false},{"pmid":"28480349","id":"PMC_28480349","title":"Complement factor P is a ligand for the natural killer cell-activating receptor NKp46.","date":"2017","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28480349","citation_count":102,"is_preprint":false},{"pmid":"18815119","id":"PMC_18815119","title":"Regulatory role of NKp44, NKp46, DNAM-1 and NKG2D receptors in the interaction between NK cells and trophoblast cells. Evidence for divergent functional profiles of decidual versus peripheral NK cells.","date":"2008","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18815119","citation_count":99,"is_preprint":false},{"pmid":"21030563","id":"PMC_21030563","title":"NKp46 and DNAM-1 NK-cell receptors drive the response to human cytomegalovirus-infected myeloid dendritic cells overcoming viral immune evasion strategies.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21030563","citation_count":97,"is_preprint":false},{"pmid":"22105417","id":"PMC_22105417","title":"Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD.","date":"2011","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22105417","citation_count":97,"is_preprint":false},{"pmid":"22231698","id":"PMC_22231698","title":"Human NK Cells induce neutrophil apoptosis via an NKp46- and Fas-dependent mechanism.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22231698","citation_count":95,"is_preprint":false},{"pmid":"19846871","id":"PMC_19846871","title":"The natural cytotoxicity receptor NKp46 is dispensable for IL-22-mediated innate intestinal immune defense against Citrobacter rodentium.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19846871","citation_count":91,"is_preprint":false},{"pmid":"21901096","id":"PMC_21901096","title":"Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin.","date":"2011","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/21901096","citation_count":89,"is_preprint":false},{"pmid":"36635380","id":"PMC_36635380","title":"Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123.","date":"2023","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/36635380","citation_count":83,"is_preprint":false},{"pmid":"27736647","id":"PMC_27736647","title":"NK Cell Recognition of Candida glabrata through Binding of NKp46 and NCR1 to Fungal Ligands Epa1, Epa6, and Epa7.","date":"2016","source":"Cell host & microbe","url":"https://pubmed.ncbi.nlm.nih.gov/27736647","citation_count":78,"is_preprint":false},{"pmid":"20404273","id":"PMC_20404273","title":"Tumor immunoediting by NKp46.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20404273","citation_count":75,"is_preprint":false},{"pmid":"22212381","id":"PMC_22212381","title":"Innate immunity in multiple sclerosis white matter lesions: expression of natural cytotoxicity triggering receptor 1 (NCR1).","date":"2012","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/22212381","citation_count":69,"is_preprint":false},{"pmid":"21695691","id":"PMC_21695691","title":"Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment.","date":"2011","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21695691","citation_count":69,"is_preprint":false},{"pmid":"18941207","id":"PMC_18941207","title":"Human NK cells kill resting but not activated microglia via NKG2D- and NKp46-mediated recognition.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18941207","citation_count":65,"is_preprint":false},{"pmid":"16371024","id":"PMC_16371024","title":"NKp46 and NKG2D receptor expression in NK cells with CD56dim and CD56bright phenotype: regulation by histamine and reactive oxygen species.","date":"2006","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/16371024","citation_count":62,"is_preprint":false},{"pmid":"23181063","id":"PMC_23181063","title":"Mapping of NKp46(+) Cells in Healthy Human Lymphoid and Non-Lymphoid Tissues.","date":"2012","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23181063","citation_count":62,"is_preprint":false},{"pmid":"15356098","id":"PMC_15356098","title":"Rat NKp46 activates natural killer cell cytotoxicity and is associated with FcepsilonRIgamma and CD3zeta.","date":"2004","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/15356098","citation_count":59,"is_preprint":false},{"pmid":"11745374","id":"PMC_11745374","title":"Identification, molecular cloning and functional characterization of NKp46 and NKp30 natural cytotoxicity receptors in Macaca fascicularis NK cells.","date":"2001","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11745374","citation_count":58,"is_preprint":false},{"pmid":"30224819","id":"PMC_30224819","title":"NK cell receptor NKG2D sets activation threshold for the NCR1 receptor early in NK cell development.","date":"2018","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30224819","citation_count":56,"is_preprint":false},{"pmid":"21364281","id":"PMC_21364281","title":"NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human.","date":"2011","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/21364281","citation_count":56,"is_preprint":false},{"pmid":"22539298","id":"PMC_22539298","title":"NKp46 expression discriminates porcine NK cells with different functional properties.","date":"2012","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22539298","citation_count":55,"is_preprint":false},{"pmid":"31212870","id":"PMC_31212870","title":"Indoleamine-2,3-Dioxygenase in Thyroid Cancer Cells Suppresses Natural Killer Cell Function by Inhibiting NKG2D and NKp46 Expression via STAT Signaling Pathways.","date":"2019","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31212870","citation_count":55,"is_preprint":false},{"pmid":"21849674","id":"PMC_21849674","title":"Recognition and killing of human and murine pancreatic beta cells by the NK receptor NKp46.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21849674","citation_count":52,"is_preprint":false},{"pmid":"28956765","id":"PMC_28956765","title":"Control of the HIV-1 DNA Reservoir Is Associated In Vivo and In Vitro with NKp46/NKp30 (CD335 CD337) Inducibility and Interferon Gamma Production by Transcriptionally Unique NK Cells.","date":"2017","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/28956765","citation_count":50,"is_preprint":false},{"pmid":"23602571","id":"PMC_23602571","title":"Neuraminidase-mediated, NKp46-dependent immune-evasion mechanism of influenza viruses.","date":"2013","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/23602571","citation_count":50,"is_preprint":false},{"pmid":"11606250","id":"PMC_11606250","title":"NKp46.","date":"2001","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11606250","citation_count":48,"is_preprint":false},{"pmid":"22615821","id":"PMC_22615821","title":"Elucidating the mechanisms of influenza virus recognition by Ncr1.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22615821","citation_count":48,"is_preprint":false},{"pmid":"26441997","id":"PMC_26441997","title":"NKp46 Clusters at the Immune Synapse and Regulates NK Cell Polarization.","date":"2015","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26441997","citation_count":47,"is_preprint":false},{"pmid":"30448772","id":"PMC_30448772","title":"NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study.","date":"2018","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/30448772","citation_count":46,"is_preprint":false},{"pmid":"24769842","id":"PMC_24769842","title":"Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients.","date":"2014","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/24769842","citation_count":46,"is_preprint":false},{"pmid":"25991472","id":"PMC_25991472","title":"Expression of NKp30, NKp46 and DNAM-1 activating receptors on resting and IL-2 activated NK cells from healthy donors according to CMV-serostatus and age.","date":"2015","source":"Biogerontology","url":"https://pubmed.ncbi.nlm.nih.gov/25991472","citation_count":44,"is_preprint":false},{"pmid":"27183613","id":"PMC_27183613","title":"Phenotypic and Functional Plasticity of Murine Intestinal NKp46+ Group 3 Innate Lymphoid Cells.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/27183613","citation_count":41,"is_preprint":false},{"pmid":"35024767","id":"PMC_35024767","title":"The transcription factor HIF-1α mediates plasticity of NKp46+ innate lymphoid cells in the gut.","date":"2022","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35024767","citation_count":40,"is_preprint":false},{"pmid":"21819408","id":"PMC_21819408","title":"NKp46+ cells express granulysin in multiple cutaneous adverse drug reactions.","date":"2011","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/21819408","citation_count":40,"is_preprint":false},{"pmid":"26372382","id":"PMC_26372382","title":"Lysis of HIV-1-infected autologous CD4+ primary T cells by interferon-alpha-activated NK cells requires NKp46 and NKG2D.","date":"2015","source":"AIDS (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/26372382","citation_count":40,"is_preprint":false},{"pmid":"27933061","id":"PMC_27933061","title":"NCR1 Expression Identifies Canine Natural Killer Cell Subsets with Phenotypic Similarity to Human Natural Killer Cells.","date":"2016","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27933061","citation_count":39,"is_preprint":false},{"pmid":"17972960","id":"PMC_17972960","title":"Expression of ligands to NKp46 in benign and malignant melanocytes.","date":"2007","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/17972960","citation_count":39,"is_preprint":false},{"pmid":"22253448","id":"PMC_22253448","title":"Role of runt-related transcription factor 3 (RUNX3) in transcription regulation of natural cytotoxicity receptor 1 (NCR1/NKp46), an activating natural killer (NK) cell receptor.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22253448","citation_count":37,"is_preprint":false},{"pmid":"24225754","id":"PMC_24225754","title":"Expression of the activating receptor, NKp46 (CD335), in human natural killer and T-cell neoplasia.","date":"2013","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24225754","citation_count":36,"is_preprint":false},{"pmid":"24882008","id":"PMC_24882008","title":"NK cell receptor NKp46 regulates graft-versus-host disease.","date":"2014","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/24882008","citation_count":35,"is_preprint":false},{"pmid":"21191411","id":"PMC_21191411","title":"Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sézary syndrome patients.","date":"2010","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/21191411","citation_count":35,"is_preprint":false},{"pmid":"26876298","id":"PMC_26876298","title":"Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia.","date":"2016","source":"Archives of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/26876298","citation_count":35,"is_preprint":false},{"pmid":"27587403","id":"PMC_27587403","title":"Neutrophils can disarm NK cell response through cleavage of NKp46.","date":"2016","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/27587403","citation_count":34,"is_preprint":false},{"pmid":"21345198","id":"PMC_21345198","title":"NKp46 defines ovine cells that have characteristics corresponding to NK cells.","date":"2011","source":"Veterinary research","url":"https://pubmed.ncbi.nlm.nih.gov/21345198","citation_count":33,"is_preprint":false},{"pmid":"29661825","id":"PMC_29661825","title":"NKp46 Calibrates Tumoricidal Potential of Type 1 Innate Lymphocytes by Regulating TRAIL Expression.","date":"2018","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/29661825","citation_count":33,"is_preprint":false},{"pmid":"30713781","id":"PMC_30713781","title":"Circulating NKp46+ Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung Cancer.","date":"2018","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/30713781","citation_count":33,"is_preprint":false},{"pmid":"25142413","id":"PMC_25142413","title":"Conditional ablation of NKp46+ cells using a novel Ncr1(greenCre) mouse strain: NK cells are essential for protection against pulmonary B16 metastases.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25142413","citation_count":32,"is_preprint":false},{"pmid":"25435072","id":"PMC_25435072","title":"Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a.","date":"2014","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25435072","citation_count":32,"is_preprint":false},{"pmid":"24639352","id":"PMC_24639352","title":"NKp46+ CD3+ cells: a novel nonconventional T cell subset in cattle exhibiting both NK cell and T cell features.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24639352","citation_count":32,"is_preprint":false},{"pmid":"27471504","id":"PMC_27471504","title":"Porcine CD3(+)NKp46(+) Lymphocytes Have NK-Cell Characteristics and Are Present in Increased Frequencies in the Lungs of Influenza-Infected Animals.","date":"2016","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27471504","citation_count":32,"is_preprint":false},{"pmid":"22621189","id":"PMC_22621189","title":"CD158k/KIR3DL2 and NKp46 are frequently expressed in transformed mycosis fungoides.","date":"2012","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/22621189","citation_count":32,"is_preprint":false},{"pmid":"24319263","id":"PMC_24319263","title":"Anti-HIV antibody-dependent activation of NK cells impairs NKp46 expression.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24319263","citation_count":31,"is_preprint":false},{"pmid":"21214542","id":"PMC_21214542","title":"Expansion of 2B4+ natural killer (NK) cells and decrease in NKp46+ NK cells in response to influenza.","date":"2011","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21214542","citation_count":31,"is_preprint":false},{"pmid":"23538009","id":"PMC_23538009","title":"Successfully treated HIV-infected patients have differential expression of NK cell receptors (NKp46 and NKp30) according to AIDS status at presentation.","date":"2013","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/23538009","citation_count":31,"is_preprint":false},{"pmid":"32204481","id":"PMC_32204481","title":"Understanding the Synergy of NKp46 and Co-Activating Signals in Various NK Cell Subpopulations: Paving the Way for More Successful NK-Cell-Based Immunotherapy.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32204481","citation_count":30,"is_preprint":false},{"pmid":"18329100","id":"PMC_18329100","title":"Bovine WC1(-) gammadeltaT cells incubated with IL-15 express the natural cytotoxicity receptor CD335 (NKp46) and produce IFN-gamma in response to exogenous IL-12 and IL-18.","date":"2008","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18329100","citation_count":29,"is_preprint":false},{"pmid":"25431955","id":"PMC_25431955","title":"An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25431955","citation_count":29,"is_preprint":false},{"pmid":"23649470","id":"PMC_23649470","title":"Characterization of a novel NKG2D and NKp46 double-mutant mouse reveals subtle variations in the NK cell repertoire.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23649470","citation_count":29,"is_preprint":false},{"pmid":"39300068","id":"PMC_39300068","title":"GPX4 restricts ferroptosis of NKp46+ILC3s to control intestinal inflammation.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/39300068","citation_count":28,"is_preprint":false},{"pmid":"29885835","id":"PMC_29885835","title":"HIF-1α induces immune escape of prostate cancer by regulating NCR1/NKp46 signaling through miR-224.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29885835","citation_count":28,"is_preprint":false},{"pmid":"29636640","id":"PMC_29636640","title":"MiR-544 promotes immune escape through downregulation of NCR1/NKp46 via targeting RUNX3 in liver cancer.","date":"2018","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/29636640","citation_count":27,"is_preprint":false},{"pmid":"21341264","id":"PMC_21341264","title":"Lymphotoxin-β receptor-independent development of intestinal IL-22-producing NKp46+ innate lymphoid cells.","date":"2011","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21341264","citation_count":27,"is_preprint":false},{"pmid":"29440507","id":"PMC_29440507","title":"Cutting Edge: Check Your Mice-A Point Mutation in the Ncr1 Locus Identified in CD45.1 Congenic Mice with Consequences in Mouse Susceptibility to Infection.","date":"2018","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/29440507","citation_count":27,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49058,"output_tokens":9250,"usd":0.142962,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19346,"output_tokens":5633,"usd":0.118777,"stage2_stop_reason":"end_turn"},"total_usd":0.261739,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"Surface density of NKp46 on NK clones directly correlates with natural cytotoxicity against HLA-class I-unprotected target cells; antibody-mediated masking of NKp46 inhibits cytolysis, establishing NKp46 as a principal activating receptor mediating natural cytotoxicity.\",\n      \"method\": \"Monoclonal antibody masking assay, NK clone cytotoxicity assay (chromium release)\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional blocking with mAb plus correlation across multiple NK clones and fresh NK cells, replicated across donors and target cell types\",\n      \"pmids\": [\"10359120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"NKp46 ligation on NK cells activates phosphatidylinositol 3-kinase (PI3K), and PI3K inhibitors (LY294002, wortmannin) block NK cell-mediated lysis of autologous antigen-presenting cells and reduce Akt/PKB activation triggered by NKp30 or NKp46 engagement.\",\n      \"method\": \"Redirected killing assay, PI3K inhibitor treatment, Akt/PKB activation assay\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional assay with pharmacological inhibitors and signaling readout, single lab but two orthogonal methods\",\n      \"pmids\": [\"11385609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"NKp46 receptor expression (mRNA) is upregulated on NK cells in response to M. tuberculosis-infected monocytes, and antibody-mediated masking of NKp46 markedly inhibits NK lysis of infected monocytes, establishing NKp46 as a mediator of NK killing of intracellularly bacterium-infected cells.\",\n      \"method\": \"RT-PCR for NKp46 mRNA, antibody-blocking cytotoxicity assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — blocking antibody functional assay plus mRNA quantification, single lab\",\n      \"pmids\": [\"11907104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"NKp46 directly binds influenza and Sendai virus hemagglutinins in a sialic acid-dependent manner; the interaction is primarily mediated via alpha2,6-linked sialic acid carried on NKp46. Recognition of target cells (both viral and tumor) is confined to the membrane-proximal domain of NKp46. A highly conserved O-glycosylated residue, Thr225, plays a dual critical role in NKp46 interactions with both viral hemagglutinins and unknown tumor ligands through different mechanisms.\",\n      \"method\": \"Direct binding assay, site-directed mutagenesis of NKp46 residues, sialic acid modification experiments, cytotoxicity assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro binding assays with mutagenesis defining specific residues and glycosylation requirements, multiple viral strains tested\",\n      \"pmids\": [\"14504081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Rat NKp46 is an activating NK cell receptor; immunoprecipitation demonstrated that rat NKp46 associates with the ITAM-bearing adaptor proteins CD3ζ and FcεRIγ, establishing its signaling mechanism analogous to CD16.\",\n      \"method\": \"Immunoprecipitation/Western blot, redirected lysis assay, flow cytometry\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal IP demonstrating adaptor association plus functional redirected lysis, single lab\",\n      \"pmids\": [\"15356098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"L-kynurenine, a tryptophan catabolite produced by IDO, prevents cytokine-mediated up-regulation of NKp46 surface expression (at both transcriptional and protein levels) and impairs NK cell killing of targets recognized via NKp46; this effect is specific to NKp46 and NKG2D but not NKp30 or CD16, and is reversible upon washing.\",\n      \"method\": \"Flow cytometry for receptor expression, NK cytotoxicity assay, RT-PCR for mRNA levels\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor-level and functional readouts at protein and mRNA levels, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"16902152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"NCR1 (mouse ortholog of NKp46) is required for in vivo control of influenza virus infection; Ncr1-deficient mice (both 129/Sv and C57BL/6) succumb to lethal influenza infection, and NK cells accumulate at the infection site as tracked by GFP reporter.\",\n      \"method\": \"Ncr1(gfp/gfp) knockout mouse, influenza infection survival model, GFP-based NK cell tracking\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic knockout with defined lethal phenotype, replicated in two mouse strains\",\n      \"pmids\": [\"16565719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Adenosine suppresses NKp46-receptor crosslinking-mediated NK cell cytotoxic activity and cytokine/chemokine production via A2A adenosine receptor signaling, increased cAMP, and activation of PKA isozyme I (PKA I), but not PKA II.\",\n      \"method\": \"NKp46 receptor crosslinking assay, adenosine receptor pharmacology, PKA subunit blockade\",\n      \"journal\": \"Immunologic research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor crosslinking functional assay with specific PKA isoform pharmacological dissection, single lab\",\n      \"pmids\": [\"17337770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"NKp46 recognizes influenza hemagglutinin on infected dendritic cells; antibody blockade of NKp46 (along with NKG2D) inhibits CD69 upregulation and IFN-γ production (but not enhanced cytolysis) of resting NK cells activated by influenza-infected DCs.\",\n      \"method\": \"Antibody-blocking assay, NK cell activation readouts (CD69, IFN-γ, cytolysis), influenza-infected DC co-culture\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional blocking with defined ligand (HA) plus multiple activation readouts, single lab\",\n      \"pmids\": [\"17312110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"NKp46/CD335 is expressed by NK cells across all mouse strains and multiple monkey species; mouse NKp46 triggers NK cell effector function in a redirected lysis assay; NKp46 expression is detected from the immature CD122+NK1.1+DX5- stage onward; human NKp46 promoter drives NK-cell-selective expression in vitro and in vivo in transgenic mice.\",\n      \"method\": \"Flow cytometry across species, redirected lysis assay, transgenic mice with NKp46 promoter-driven EGFP and diphtheria toxin receptor\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple species characterization, functional triggering assay, in vivo transgenic model with selective NK ablation\",\n      \"pmids\": [\"17360655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"In human decidual NK (dNK) cells, antibody-mediated engagement of NKp46 (but not NKp30) induces intracellular calcium mobilization, perforin polarization, granule exocytosis, and efficient target cell lysis; NKp46-mediated cytotoxicity is co-activated by CD2 but blocked by NKG2A co-engagement. Conversely, NKp30 (but not NKp46) engagement triggers IFN-γ, TNF-α, and chemokine production in dNK cells.\",\n      \"method\": \"mAb-specific receptor engagement, calcium mobilization assay, perforin polarization, granule exocytosis assay, cytotoxicity assay, cytokine measurement\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal functional readouts with receptor-specific mAb engagement and co-receptor dissection\",\n      \"pmids\": [\"18713971\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"NCR1 (mouse NKp46 ortholog) binds to NKp46 ligands expressed on hepatic stellate cells (HSC); NCR1-deficient mice develop enhanced liver fibrosis in a carbon tetrachloride model; murine and human HSC are killed in an NKp46/NCR1-dependent manner as shown by NKp46-Fc fusion protein binding and antibody-blocking cytotoxicity assays.\",\n      \"method\": \"NCR1/NKp46-Fc fusion protein staining, Ncr1(gfp/gfp) knockout mouse (CCl4 fibrosis model), NK killing assay with antibody blocking\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic KO with fibrosis phenotype, in vitro killing assay with receptor blocking, receptor-Fc binding, human and mouse cells\",\n      \"pmids\": [\"22198715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"NKp46 recognizes specific heparan sulfate/heparin sequences on cancer cells; NKp46 binds highly charged HS/heparin structures, with binding affinities approximately one order of magnitude lower than NKp30 and NKp44; HS/heparin binding to NKp46 is relevant for tumor cell binding and NK cell activation.\",\n      \"method\": \"Microarray with heparan sulfate oligosaccharide library, surface plasmon resonance, NK cell activation assay\",\n      \"journal\": \"Journal of proteome research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — SPR quantitative binding assay with defined synthetic HS structures and functional NK activation readout, single lab\",\n      \"pmids\": [\"19196184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"NKp46 is required for in vivo development of type 1 diabetes; NKp46 recognizes an unknown ligand on mouse and human pancreatic β cells, and NKp46 engagement by β cells leads to NK cell degranulation. NCR1-deficient mice show less streptozotocin-induced diabetes, and soluble NKp46 protein injection into NOD mice during early insulitis prevents diabetes development.\",\n      \"method\": \"Ncr1(gfp/gfp) knockout mouse (streptozotocin diabetes model), NOD mouse model with soluble NKp46 injection, NK degranulation assay\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with defined disease phenotype, soluble receptor competition in vivo, multiple mouse models, human β cell confirmation\",\n      \"pmids\": [\"20023661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"NCR1 is required for in vivo eradication of PD1.6 lymphoma cells; a cell reporter assay identified a NCR1 ligand on PD1.6 lymphoma cells; in Ncr1(gfp/gfp) knockout mice, PD1.6 lymphoma grows progressively whereas wild-type mice reject tumors; PD1.6 cells are less killed in vitro and in vivo in the absence of NKp46/NCR1.\",\n      \"method\": \"Cell reporter assay for ligand detection, Ncr1(gfp/gfp) knockout mouse tumor model, in vitro and in vivo NK killing assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with in vivo tumor growth phenotype, functional in vitro killing assay, ligand identification by reporter assay\",\n      \"pmids\": [\"19201876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In human NK cells, NKp46 engagement induces neutrophil apoptosis in a cell-contact-dependent and caspase-dependent manner through the Fas pathway; antibody blockade of NKp46 (along with Fas pathway inhibition) inhibits this NK-induced neutrophil apoptosis.\",\n      \"method\": \"NK-neutrophil co-culture, antibody blocking of NKp46, caspase activation assay, Fas pathway analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-contact functional assay with receptor-specific blocking and caspase pathway readout, single lab\",\n      \"pmids\": [\"22231698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Human and murine pancreatic β cells express an unknown NKp46 ligand and are killed in an NKp46-dependent manner; recognition is confined to the membrane-proximal domain and stalk region of NKp46; glycosylated residues Thr125 and Asn216 on NKp46 are critical for β cell ligand recognition.\",\n      \"method\": \"NKp46-Fc fusion protein binding, site-directed mutagenesis of NKp46 glycosylation sites, NK killing assay with antibody blocking, flow cytometry\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis defining specific glycosylation residues, receptor-Fc binding, functional killing assay, both human and mouse cells\",\n      \"pmids\": [\"21849674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NKp46 forms microclusters at the immune synapse between NK cells and target cells; overexpression of human NKp46 increases F-actin accumulation at the immune synapse, and knockdown of NKp46 in primary NK cells decreases F-actin recruitment; NKp46 expression linearly correlates with lytic granule polarization to the immune synapse.\",\n      \"method\": \"Live cell imaging, F-actin staining at immune synapse, NKp46 overexpression and knockdown, lytic granule polarization assay\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — live imaging with gain/loss-of-function and multiple functional readouts, single lab\",\n      \"pmids\": [\"26441997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"A loss-of-function mutation in the Ncr1 gene (identified by N-ethyl-N-nitrosourea mutagenesis and whole-genome sequencing) results in hyperresponsive NK cells with increased antiviral resistance; NKp46 down-regulates NK cell activity by promoting Helios transcription factor expression in NK cells; NKp46 blockade in vivo enhances NK cell reactivity.\",\n      \"method\": \"ENU mutagenesis screen, whole-genome sequencing, Ncr1 loss-of-function mutant mice, viral infection models, Helios expression analysis, in vivo NKp46 blockade\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — unbiased genetic screen with whole-genome sequencing, in vivo functional validation, transcription factor mechanistic link\",\n      \"pmids\": [\"22267813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NKp46 and NKp30 on NK cells are required for NK-mediated killing of oHSV-infected glioblastoma cells, as their ligands are upregulated on infected cells; in Ncr1(-/-) mice and an Ncr1(-/-) NK cell adoptive transfer model, HSV titers and oHSV efficacy are increased, demonstrating that NCR1-mediated NK cell activation limits oncolytic virotherapy.\",\n      \"method\": \"Ncr1(-/-) mouse, antibody blocking of NKp46/NKp30, NK cytotoxicity assay, adoptive transfer model, HSV titer measurement\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO and adoptive transfer with defined functional phenotype, antibody blocking, in vivo and in vitro confirmation\",\n      \"pmids\": [\"23178246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NKp46/NCR1 is directly involved in killing of B16 melanoma and Lewis lung carcinoma (D122) cells; an unknown ligand for NKp46/NCR1 is expressed on these tumor cells including those generated in vivo; NCR1-deficient mice show impaired control of B16 and D122 metastasis in spontaneous metastasis models.\",\n      \"method\": \"Ncr1(gfp/gfp) knockout mouse, NKp46-Fc fusion protein staining, spontaneous metastasis models, NK killing assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with in vivo metastasis phenotype, receptor-Fc binding to characterize ligand properties, in vitro and in vivo killing assays\",\n      \"pmids\": [\"22308311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"RUNX3 transcription factor directly regulates NCR1/NKp46 expression; two cis-regulatory elements near the NCR1 gene act as essential promoter and tissue-dependent enhancer/repressor; the enhancer/repressor contains a RUNX recognition motif that preferentially binds RUNX3; dominant-negative RUNX interference decreases Ncr1 expression, and RUNX3 overexpression increases it.\",\n      \"method\": \"Reporter assay, dominant-negative RUNX expression, RUNX3 overexpression, EMSA/binding to RUNX motif, mRNA quantification\",\n      \"journal\": \"Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptional regulatory mechanism with dominant negative and overexpression, single lab with multiple methods\",\n      \"pmids\": [\"22253448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Influenza neuraminidase (NA) removes sialic acid residues from NKp46, thereby reducing NKp46 recognition of viral hemagglutinin (HA) and enabling influenza immune evasion; NA inhibitors (used clinically) restore NKp46 recognition by blocking this sialic acid removal; this mechanism was validated in vitro and in vivo.\",\n      \"method\": \"NA inhibitor experiments (in vitro and in vivo), sialic acid analysis, NKp46-HA recognition assay, influenza infection model\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mechanistic characterization of sialic acid removal from NKp46 by NA with pharmacological rescue, in vitro and in vivo validation\",\n      \"pmids\": [\"23602571\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Ncr1 recognizes influenza virus in a sialic acid-dependent manner; N-glycosylation is important for Ncr1 binding to viral hemagglutinin, but none of the predicted N-glycosylated residues are individually essential, indicating other unidentified N-glycosylated residues mediate recognition; N-glycosylation plays little role in Ncr1 recognition of mouse tumor cell lines.\",\n      \"method\": \"Mutagenesis of predicted N-glycosylation sites, sialic acid-dependent binding assay, influenza infection of Ncr1 knockout mice\",\n      \"journal\": \"PLoS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis with binding assay, but key residues not fully identified, single lab\",\n      \"pmids\": [\"22615821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Type I IFN signaling directly on T cells protects them from NCR1-mediated NK cell killing; Ifnar1(-/-) T cells exhibit elevated NCR1 ligand expression upon LCMV infection, rendering them targets for NCR1-dependent NK cell attack; NK cell depletion fully restores early expansion of Ifnar1(-/-) T cells, and NCR1 mediates the perforin-dependent killing.\",\n      \"method\": \"Ifnar1(-/-) mice, NK cell depletion, NCR1-blocking experiments, LCMV infection model, NCR1 ligand expression assay\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with NK depletion epistasis, NCR1 ligand upregulation mechanistic link, in vivo LCMV infection model\",\n      \"pmids\": [\"24909889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NKp46-deficient mice show exacerbated graft-versus-host disease (GVHD) with rapid mortality from commensal bacterial infection after HSCT; the exacerbated GVHD results from altered immune cell responses to stimulation by immature dendritic cells in the absence of NKp46.\",\n      \"method\": \"Ncr1(gfp/gfp) knockout mouse, HSCT model, GVHD assessment, bacterial infection analysis, DC stimulation assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with in vivo GVHD phenotype and partial mechanistic link to DC stimulation, single lab\",\n      \"pmids\": [\"24882008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NKp46 and its mouse ortholog NCR1 directly recognize C. glabrata adhesins Epa1, Epa6, and Epa7 as fungal ligands; NCR1-knockout mice show impaired control of C. glabrata infection in vitro and in vivo, and clearance of systemic infections depends on Epa1/6/7 recognition by NCR1.\",\n      \"method\": \"NCR1 knockout mouse (in vitro/in vivo C. glabrata infection), receptor-ligand binding with defined fungal adhesins, fungal infection survival assay\",\n      \"journal\": \"Cell host & microbe\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — specific ligand identification with genetic KO validation in vitro and in vivo, defined molecular interaction\",\n      \"pmids\": [\"27736647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Neutrophil-derived cathepsin G (but not elastase or proteinase 3) cleaves NKp46 on NK cells in a time- and concentration-dependent manner, severely impairing NKp46-mediated IFN-γ production and NK cell degranulation; cystic fibrosis patient sputa (high in cathepsin G) also downregulate NKp46 on NK cells.\",\n      \"method\": \"Flow cytometry, Western blot, mass spectrometry, NK cell functional assay, CF patient sputum treatment\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — protease-specific cleavage identified by mass spectrometry with functional consequence, single lab\",\n      \"pmids\": [\"27587403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"NKp46 binds complement factor P (CFP/properdin), a soluble plasma glycoprotein; NKp46+ group 1 ILCs are required for survival of Neisseria meningitidis infection in mice, and the beneficial effects of CFP treatment in Nm infection are dependent on NKp46 and NKp46+ ILCs.\",\n      \"method\": \"Binding assay (NKp46-CFP interaction), NKp46/NCR1-deficient mice, Nm infection survival model, CFP treatment experiments\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct binding of soluble ligand identified with genetic KO validation in vivo infection model, CFP-rescue experiment\",\n      \"pmids\": [\"28480349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NKp46 signaling (via human NKp46 and mouse Ncr1) induces IFN-γ secretion from intratumoral NK cells; NKp46/Ncr1-mediated IFN-γ production leads to increased expression of fibronectin 1 (FN1) in tumors, altering primary tumor architecture and decreasing metastasis formation; IFN-γ injection or transgenic Ncr1 overexpression in mice reduces metastasis.\",\n      \"method\": \"Reflectance confocal microscopy (in vivo imaging), Ncr1 knockout mouse, IFN-γ injection, Ncr1 transgenic overexpression, FN1 expression analysis\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo imaging with genetic KO and transgenic overexpression, IFN-γ injection rescue, defined FN1 molecular mechanism\",\n      \"pmids\": [\"29329948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NKG2D specifically sets the activation threshold for NCR1 (NKp46) through a process requiring the adaptor DAP12; NKG2D engagement before the immature NK cell stage increases CD3ζ expression, and reduced CD3ζ in Klrk1(-/-) (NKG2D-deficient) mice is associated with enhanced NCR1 signal transduction; CD3ζ deficiency results in hyper-responsiveness to NCR1 stimulation.\",\n      \"method\": \"Klrk1(-/-) mouse, DAP12-deficient mouse, CD3ζ expression analysis, in vitro NCR1 stimulation, MCMV and tumor challenge models\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with multiple KO strains, CD3ζ adaptor mechanistic link, replicated across tumor and viral infection models\",\n      \"pmids\": [\"30224819\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NKp46 controls TRAIL expression on ILC1s; in NKp46-deficient mice, ILC1s fail to express normal TRAIL surface levels, resulting in diminished cytotoxicity toward TRAIL receptor-positive targets.\",\n      \"method\": \"NKp46-deficient mouse, TRAIL expression analysis on ILC1s, cytotoxicity assay against TRAIL receptor-positive targets\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with specific molecular (TRAIL) and functional (cytotoxicity) readouts, single lab\",\n      \"pmids\": [\"29661825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Poxviral hemagglutinin (HA) from vaccinia virus and ectromelia virus acts as a ligand for NKp46 (and NKp30); poxviral HA on infected cell surfaces or as soluble protein stimulates NKp46-triggered activation while blocking NKp30 activation, demonstrating differential receptor-ligand effects; this was validated using NK cells with selectively silenced NCR expression and NCR-CD3ζ reporter cells.\",\n      \"method\": \"NCR-CD3ζ reporter cell assay, NCR-specific siRNA silencing, recombinant soluble HA, NK cell activation assay\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter cell assay plus silenced NCR expression, defined recombinant ligand, single lab\",\n      \"pmids\": [\"21901096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NKp46 recognizes externalized calreticulin (ecto-CRT) on the cell surface as its endogenous ligand; ecto-CRT translocates from the ER to the cell membrane during ER stress (hallmark of chemotherapy-induced immunogenic cell death, flavivirus infection, and senescence); NKp46 specifically binds the P domain of ecto-CRT and caps with ecto-CRT at NK immune synapses; NCR1-deficient human and mouse NK cells are impaired in killing of ZIKV-infected, ER-stressed, senescent, and ecto-CRT-expressing cancer cells; NKp46 recognition of ecto-CRT controls B16 melanoma and RAS-driven lung cancers in vivo.\",\n      \"method\": \"Co-immunoprecipitation, NKp46-ecto-CRT binding assay, CALR knockout/knockdown, GPI-anchored CRT ectopic expression, NK immune synapse imaging, NCR1-deficient mouse tumor models, ZIKV infection model\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — endogenous ligand identified by multiple orthogonal methods (binding, KO, KD, ectopic expression, mutagenesis of P domain, immune synapse imaging) in single rigorous study, in vivo validation in multiple models\",\n      \"pmids\": [\"37020026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MiR-224 overexpression in NK cells reduces NCR1/NKp46 expression; HIF-1α increases miR-224 levels to suppress NCR1, thereby inhibiting NK cell killing of prostate cancer; dual luciferase reporter assay confirmed miR-224 directly targets the NCR1 3'UTR.\",\n      \"method\": \"miRNA overexpression, dual luciferase reporter assay, flow cytometry, NK cytotoxicity assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — luciferase reporter and overexpression, single lab, limited mechanistic follow-up\",\n      \"pmids\": [\"29885835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MiR-544 directly targets RUNX3 and negatively regulates NCR1/NKp46 in NK cells; miR-544 overexpression inhibits NK cytotoxicity by downregulating IFN-γ and reducing NCR1, promoting immune escape of liver cancer cells in vivo and in vitro.\",\n      \"method\": \"miRNA mimic/inhibitor transfection, qRT-PCR, Western blot, flow cytometry, NK cytotoxicity assay, mouse liver cancer model\",\n      \"journal\": \"Cancer cell international\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — indirect regulation through miR-544/RUNX3/NCR1 axis, single lab with limited mechanistic depth on NCR1 itself\",\n      \"pmids\": [\"29636640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NKp46 ligation on NK cells in Sézary syndrome malignant CD4+ T lymphocytes delivers an inhibitory signal suppressing CD3-induced proliferation; this inhibition correlates with decreased phosphorylation of the CD3ζ chain associated with NKp46 and/or the TCR/CD3 complex.\",\n      \"method\": \"mAb-specific NKp46 engagement, proliferation assay, CD3ζ phosphorylation analysis\",\n      \"journal\": \"Journal of investigative dermatology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — NKp46 on malignant T cells (atypical context), single Co-IP/phosphorylation readout, single lab\",\n      \"pmids\": [\"21191411\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NCR1/NKp46 is a conserved activating NK cell receptor that signals through ITAM-bearing adaptors (CD3ζ and FcεRIγ) and PI3K/Akt to trigger cytotoxicity and cytokine secretion; it recognizes multiple ligands including viral hemagglutinins (via α2,6-linked sialic acid on NKp46 itself), externalized calreticulin (ecto-CRT, the principal endogenous danger ligand), complement factor P (properdin), fungal adhesins (Epa1/6/7 on C. glabrata), heparan sulfate proteoglycans on tumor cells, and unknown ligands on pancreatic β cells, hepatic stellate cells, and tumor cells; its activation threshold and TRAIL expression are calibrated by NKG2D through a DAP12–CD3ζ developmental axis; the receptor forms microclusters at the immune synapse to orchestrate F-actin recruitment and lytic granule polarization; NKp46 sialylation is required for hemagglutinin binding and is exploited by influenza neuraminidase as an immune-evasion mechanism; RUNX3 drives NK-cell-specific transcription of the NCR1 gene; and in vivo, NKp46/NCR1 is essential for control of influenza infection, type 1 diabetes, tumor metastasis, C. glabrata infection, and liver fibrosis, and it restrains GVHD and regulates adaptive T cell responses.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"NCR1 (NKp46/CD335) is a principal activating receptor of natural killer cells and group 1 innate lymphoid cells that triggers natural cytotoxicity and cytokine secretion against virally infected, tumorigenic, and stressed cells [#0, #9]. Receptor engagement associates with the ITAM-bearing adaptors CD3\\u03b6 and Fc\\u03b5RI\\u03b3 and activates PI3K/Akt signaling, driving calcium mobilization, granule polarization, and target lysis [#4, #1, #10]; at the immune synapse NKp46 forms microclusters that recruit F-actin and direct lytic granules toward the target cell [#17]. NKp46 recognizes a diverse ligand repertoire: influenza, Sendai, and poxviral hemagglutinins via sialic acid and O-/N-glycosylation on the receptor itself [#3, #32, #23], heparan sulfate structures and unknown ligands on tumor cells [#12, #20, #14], ligands on hepatic stellate cells and pancreatic \\u03b2 cells [#11, #16, #13], fungal Epa adhesins of C. glabrata [#26], complement factor P [#28], and the endogenous danger ligand externalized calreticulin, which it binds via the CRT P domain on ER-stressed, senescent, infected, and dying cells [#33]. Through these recognition events NCR1 is required in vivo for control of influenza infection, type 1 diabetes, liver fibrosis, fungal infection, and tumor metastasis, the latter in part through IFN-\\u03b3-driven fibronectin remodeling of tumor architecture [#6, #13, #11, #26, #29], while also restraining graft-versus-host disease and shaping adaptive T cell responses through perforin-dependent killing of type-I-IFN-unprotected T cells [#25, #24]. Receptor abundance and signaling are tightly calibrated transcriptionally by RUNX3 [#21], developmentally by an NKG2D\\u2013DAP12\\u2013CD3\\u03b6 axis that sets the NCR1 activation threshold and controls ILC1 TRAIL expression [#30, #31], and post-translationally by influenza neuraminidase desialylation and neutrophil cathepsin G cleavage as immune-evasion mechanisms [#22, #27].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established NKp46 as the principal activating receptor responsible for natural cytotoxicity against HLA-class-I-deficient targets, defining its core cellular role.\",\n      \"evidence\": \"mAb masking and chromium-release cytotoxicity across NK clones\",\n      \"pmids\": [\"10359120\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the signaling adaptor or downstream pathway\", \"Endogenous ligand unidentified\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Connected NKp46 ligation to an intracellular signaling pathway by showing it activates PI3K/Akt required for target lysis.\",\n      \"evidence\": \"Redirected killing with PI3K inhibitors and Akt activation readout\",\n      \"pmids\": [\"11385609\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Pharmacological inhibitors only\", \"Did not define receptor-proximal adaptor coupling to PI3K\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified the first molecular ligands (viral hemagglutinins) and showed recognition depends on \\u03b12,6-sialic acid and glycosylation on the receptor itself, mapping interactions to the membrane-proximal domain and Thr225.\",\n      \"evidence\": \"Direct binding assays with site-directed mutagenesis and sialic acid modification\",\n      \"pmids\": [\"14504081\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tumor ligand remained unknown\", \"Endogenous self-ligand not defined\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defined the signaling mechanism by demonstrating association with the ITAM-bearing adaptors CD3\\u03b6 and Fc\\u03b5RI\\u03b3, analogous to CD16.\",\n      \"evidence\": \"Reciprocal immunoprecipitation and redirected lysis in rat NKp46\",\n      \"pmids\": [\"15356098\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Rat ortholog; human stoichiometry not quantified\", \"Link from ITAM to PI3K not traced\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Provided in vivo proof that NCR1 is essential for host defense, with knockout mice dying of influenza infection.\",\n      \"evidence\": \"Ncr1(gfp/gfp) knockout mice in lethal influenza model across two strains\",\n      \"pmids\": [\"16565719\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish which viral ligand mediates protection in vivo\", \"NK effector mechanism not dissected in vivo\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed receptor surface levels are environmentally tunable, as the IDO metabolite L-kynurenine and adenosine/A2A-cAMP-PKA I signaling suppress NKp46 expression and function.\",\n      \"evidence\": \"Flow cytometry, RT-PCR, crosslinking assays with receptor and PKA-subunit pharmacology\",\n      \"pmids\": [\"16902152\", \"17337770\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of transcriptional suppression unresolved\", \"Single-lab pharmacological dissection\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Extended NCR1's in vivo roles to autoimmunity, tumor surveillance, and tissue fibrosis by linking it to \\u03b2-cell killing in diabetes, lymphoma rejection, and hepatic stellate cell killing.\",\n      \"evidence\": \"Ncr1 knockout disease models (streptozotocin/NOD diabetes, PD1.6 lymphoma, CCl4 fibrosis) with NKp46-Fc ligand staining\",\n      \"pmids\": [\"20023661\", \"19201876\", \"22198715\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous ligands on \\u03b2 cells, lymphoma, and stellate cells remained molecularly unidentified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Characterized heparan sulfate/heparin as a class of tumor-relevant NKp46 ligands and quantified binding.\",\n      \"evidence\": \"HS oligosaccharide microarray, surface plasmon resonance, and NK activation\",\n      \"pmids\": [\"19196184\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Affinities lower than NKp30/NKp44; physiological relevance on specific tumors not fully defined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Refined ligand-recognition determinants by mapping \\u03b2-cell ligand binding to the membrane-proximal/stalk region and specific glycosylated residues Thr125 and Asn216.\",\n      \"evidence\": \"NKp46-Fc binding with glycosylation-site mutagenesis and killing assays in human and mouse cells\",\n      \"pmids\": [\"21849674\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"\\u03b2-cell ligand identity still unknown\", \"Mechanistic basis for glycan dependence unresolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Revealed a self-limiting regulatory function: an Ncr1 loss-of-function mutation produces hyperresponsive NK cells, with NKp46 promoting inhibitory Helios expression.\",\n      \"evidence\": \"ENU mutagenesis, whole-genome sequencing, viral challenge, and in vivo NKp46 blockade\",\n      \"pmids\": [\"22267813\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Pathway linking NKp46 to Helios transcription not defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined the synaptic and transcriptional basis of NKp46 action by linking it to F-actin recruitment and lytic granule polarization, and to RUNX3-driven NK-specific transcription.\",\n      \"evidence\": \"Live imaging with NKp46 gain/loss-of-function; reporter assays and EMSA with RUNX3 manipulation\",\n      \"pmids\": [\"26441997\", \"22253448\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular link from microclusters to actin machinery not detailed\", \"Single-lab transcriptional data\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Established NCR1's role in tumor metastasis control and showed it limits oncolytic virotherapy by recognizing ligands on infected/tumor cells.\",\n      \"evidence\": \"Ncr1 knockout spontaneous-metastasis and oHSV glioblastoma models with NKp46-Fc staining\",\n      \"pmids\": [\"22308311\", \"23178246\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tumor and oHSV-induced ligands not molecularly identified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Uncovered an influenza immune-evasion mechanism whereby viral neuraminidase desialylates NKp46 to abolish HA recognition, reversible by clinical NA inhibitors.\",\n      \"evidence\": \"NA inhibitor experiments in vitro and in vivo with sialic acid and recognition assays\",\n      \"pmids\": [\"23602571\", \"22615821\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise N-glycosylated residues mediating HA recognition not fully identified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined an immunoregulatory role in adaptive immunity: NCR1 mediates perforin-dependent killing of T cells lacking type I IFN protection.\",\n      \"evidence\": \"Ifnar1(-/-) mice with NK depletion epistasis and NCR1 blockade in LCMV infection\",\n      \"pmids\": [\"24909889\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"NCR1 ligand upregulated on IFN-unprotected T cells not identified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified the first defined microbial protein ligands (C. glabrata Epa1/6/7 adhesins) and established NCR1 in antifungal defense.\",\n      \"evidence\": \"NCR1 knockout C. glabrata infection models with defined adhesin binding\",\n      \"pmids\": [\"27736647\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor binding interface for Epa adhesins not structurally mapped\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated a host protease evasion route in which neutrophil cathepsin G cleaves NKp46 and impairs NK function, relevant to cystic fibrosis.\",\n      \"evidence\": \"Protease specificity by mass spectrometry, Western blot, and CF sputum functional assays\",\n      \"pmids\": [\"27587403\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cleavage site and protease-resistant variants not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified a soluble plasma ligand, complement factor P (properdin), linking NKp46+ ILCs to antibacterial survival.\",\n      \"evidence\": \"NKp46-CFP binding assay with knockout mice and CFP-rescue in Neisseria infection\",\n      \"pmids\": [\"28480349\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of CFP binding for downstream signaling not detailed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established a downstream effector mechanism for metastasis control: NKp46-driven IFN-\\u03b3 increases tumor fibronectin and remodels tumor architecture.\",\n      \"evidence\": \"In vivo confocal imaging, Ncr1 knockout/transgenic overexpression, IFN-\\u03b3 injection rescue\",\n      \"pmids\": [\"29329948\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Triggering ligand on the relevant tumors not identified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined developmental calibration of the receptor: NKG2D sets the NCR1 activation threshold via DAP12-dependent CD3\\u03b6 levels, and NKp46 controls ILC1 TRAIL expression.\",\n      \"evidence\": \"Klrk1(-/-) and DAP12-deficient mice with CD3\\u03b6 analysis and MCMV/tumor challenge; TRAIL/cytotoxicity in NKp46-deficient ILC1s\",\n      \"pmids\": [\"30224819\", \"29661825\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of how CD3\\u03b6 abundance tunes NCR1 signal strength not fully resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Implicated microRNA circuits (miR-224 via HIF-1\\u03b1, miR-544 via RUNX3) in tumor-driven suppression of NCR1 expression.\",\n      \"evidence\": \"miRNA mimics/inhibitors with luciferase reporters and NK cytotoxicity assays\",\n      \"pmids\": [\"29885835\", \"29636640\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single-lab reporter/overexpression studies with limited mechanistic follow-up\", \"In vivo physiological relevance of these miRNA axes not established\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified the principal endogenous danger ligand: externalized calreticulin, bound via its P domain on ER-stressed, senescent, infected, and dying cells, unifying NCR1's recognition of stressed self.\",\n      \"evidence\": \"Co-IP, binding assays, CALR KO/KD, GPI-anchored CRT ectopic expression, synapse imaging, and NCR1-deficient tumor/ZIKV models\",\n      \"pmids\": [\"37020026\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relationship between ecto-CRT and the many previously reported unidentified cellular ligands not reconciled\", \"Structural detail of the NKp46\\u2013CRT P-domain interface not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular identities of multiple reported endogenous ligands (on tumor cells, hepatic stellate cells, \\u03b2 cells, and IFN-unprotected T cells) and how they relate to ecto-CRT remain unresolved, as does the structural basis for NCR1's glycan-dependent multi-ligand recognition.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Several disease-relevant ligands remain molecularly uncharacterized\", \"No high-resolution structure of NCR1 with an endogenous ligand\", \"Mechanism integrating diverse ligand inputs into a single ITAM signal undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 9, 10]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [3, 32, 23]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [11, 20, 33]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 4, 17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 6, 13, 26]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 4, 30]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CD247\", \"FCER1G\", \"CALR\", \"NKG2D\", \"DAP12\", \"RUNX3\", \"CFP\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}